Vertex Pharmaceuticals's annual revenues are over $500 million (see exact revenue data) and has over 1,000 employees. It is classified as operating in the Scientific Research & Development Services industry.
Note: Vertex Pharmaceuticals's revenues are gauged from an analysis of company filings.
Vertex Pharmaceuticals has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
March 18, 2009
Complete list of funding rounds and total amounts in the Company Report
Trademark applications show the products and services that Vertex Pharmaceuticals is developing and marketing.
Vertex Pharmaceuticals's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets.
Trademarks may include brand names, product names, logos and slogans.
TRIKAFTA Pharmaceutical preparations for the treatment of cystic fibrosis
AKAFTREO Pharmaceutical preparations for the treatment of cystic fibrosis
KLYTREOS Pharmaceutical preparations for the treatment of cystic fibrosis
Patent applications show Vertex Pharmaceuticals's intellectual property,
its current capabilities and future direction.
Vertex Pharmaceuticals has applied for 658 patents since 2009.
Vertex Pharmaceuticals's most recent patent was filed in June 2018 for Compounds Useful As Inhibitors Of Atr Kinase.Array
Complete list of patent applications
Determine whether Vertex Pharmaceuticals grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Vertex Pharmaceuticals is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Competition: Vertex Pharmaceuticals vs. Largest Competitors
A competitive analysis shows these companies are in the same general field as Vertex Pharmaceuticals, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are similar in business line and location to Vertex Pharmaceuticals.
While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.
These companies are in the same general field as Vertex Pharmaceuticals and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.